000 03512nam a22003855i 4500
001 289764
003 MX-SnUAN
005 20160429154722.0
007 cr nn 008mamaa
008 150903s2014 xxu| o |||| 0|eng d
020 _a9781489980021
_99781489980021
024 7 _a10.1007/9781489980021
_2doi
035 _avtls000342758
039 9 _a201509030858
_bVLOAD
_c201405050248
_dVLOAD
_y201402061134
_zstaff
040 _aMX-SnUAN
_bspa
_cMX-SnUAN
_erda
050 4 _aRC261-271
100 1 _aBrown, Kristy A.
_eautor
_9320132
245 1 0 _aObesity and Breast Cancer :
_bThe Role of Dysregulated Estrogen Metabolism /
_cby Kristy A. Brown, Evan R. Simpson.
264 1 _aNew York, NY :
_bSpringer New York :
_bImprint: Springer,
_c2014.
300 _aIx, 56 páginas 9 ilustraciones, 7 ilustraciones en color.
_brecurso en línea.
336 _atexto
_btxt
_2rdacontent
337 _acomputadora
_bc
_2rdamedia
338 _arecurso en línea
_bcr
_2rdacarrier
347 _aarchivo de texto
_bPDF
_2rda
490 0 _aSpringerBriefs in Cancer Research
500 _aSpringer eBooks
505 0 _aIntroduction -- Estrogens, adiposity and the menopause -- The link between obesity and breast cancer: Epidemiological evidence -- Adipose-derived and obesity-related factors and breast cancer -- Estrogen biosynthesis -- Therapies aimed at breaking the linkage between obesity and breast cancer -- Conclusions.
520 _aObesity is a risk factor for breast cancer in older women. A number of adipose-derived and obesity-related factors have been shown to affect tumour cell growth. These include adipokines, insulin, IGF-1 and oestrogens. The majority of obesity-related postmenopausal breast cancers are oestrogen-dependent. Since the ovaries no longer produce oestrogens after menopause, and that circulating levels are negligible, it is evident that it is the oestrogens produced locally within the breast adipose that are responsible for the increased growth of breast cancer cells. Aromatase is the enzyme that converts androgens into oestrogens and its regulation is dependent on the activity of a number of tissue-specific promoters. Targeting oestrogen biosynthesis in obesity may be useful for the prevention of breast cancer. Aromatase inhibitors are efficacious at treating postmenopausal breast cancer and recent studies suggest that they may also be useful in the prevention setting. However, these compounds inhibit the catalytic activity of aromatase and as a consequence lead to a number of undesirable side-effects, including arthralgia and possible cognitive defects due to inhibition of aromatase in the bone and brain, respectively. Novel therapies, such as those employed to treat obesity-associated disease, including anti-diabetics, may prove successful at inhibiting aromatase specifically within the breast. This SpringerBrief will explore all of these issues in depth and the authors are in a unique position to write about this topic, having extensive experience in the field of aromatase research.
590 _aPara consulta fuera de la UANL se requiere clave de acceso remoto.
700 1 _aSimpson, Evan R.
_eautor
_9320133
710 2 _aSpringerLink (Servicio en línea)
_9299170
776 0 8 _iEdición impresa:
_z9781489980014
856 4 0 _uhttp://remoto.dgb.uanl.mx/login?url=http://dx.doi.org/10.1007/978-1-4899-8002-1
_zConectar a Springer E-Books (Para consulta externa se requiere previa autentificación en Biblioteca Digital UANL)
942 _c14
999 _c289764
_d289764